These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 39429273)

  • 1. Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction: A Narrative Review.
    Maged R; Sinha M; Koneru HM; Sarwar H; Bandi VV; Tarar P; Halawa N
    Cureus; 2024 Sep; 16(9):e69623. PubMed ID: 39429273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity-related heart failure with preserved ejection fraction: new treatment strategies.
    Chrysant SG; Chrysant GS
    Hosp Pract (1995); 2019 Apr; 47(2):67-72. PubMed ID: 30712418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Sodium-Glucose Cotransporter 2 Inhibitor's Clinical Efficacy in Heart Failure With Preserved Ejection Fraction.
    Epperson J; Athar ZM; Arshad M; Chen E
    Cureus; 2024 Apr; 16(4):e57380. PubMed ID: 38694659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors.
    Heath R; Johnsen H; Strain WD; Evans M
    Diabetes Ther; 2022 Feb; 13(2):241-250. PubMed ID: 35084695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions.
    Passantino A; Rizzo C; Scrutinio D; Palazzuoli A
    Heart Fail Rev; 2023 May; 28(3):683-695. PubMed ID: 34725782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
    Starr JA; Pinner NA
    Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).
    Ito S; Nakajima Y; Fukuda H; Izumi C; Nakazawa G; Yamashita H; Matsuhisa H; Inoko M; Toyoda S; Takiuchi S; Kataoka T; Izumiya Y; Abe Y; Sozu T; Sakata Y; Emoto M; Inoue T; Kitakaze M
    Cardiovasc Drugs Ther; 2024 May; ():. PubMed ID: 38727896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
    Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
    Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction - The New Frontier.
    Aguiar-Neves I; Santos-Ferreira D; Fontes-Carvalho R
    Rev Cardiovasc Med; 2023 Jan; 24(1):1. PubMed ID: 39076855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Hamid AK; Tayem AA; Al-Aish ST; Al Sakini AS; Hadi DD; Al-Aish RT
    Ther Adv Cardiovasc Dis; 2024; 18():17539447241289067. PubMed ID: 39400108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.
    Anker SD; Butler J; Filippatos GS; Jamal W; Salsali A; Schnee J; Kimura K; Zeller C; George J; Brueckmann M; Zannad F; Packer M;
    Eur J Heart Fail; 2019 Oct; 21(10):1279-1287. PubMed ID: 31523904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is it time for class I recommendation for sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction?: An updated systematic review and meta-analysis.
    Treewaree S; Kulthamrongsri N; Owattanapanich W; Krittayaphong R
    Front Cardiovasc Med; 2023; 10():1046194. PubMed ID: 36824458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review.
    Mentz RJ; Brunton SA; Rangaswami J
    Cardiovasc Diabetol; 2023 Nov; 22(1):316. PubMed ID: 37974185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
    Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
    Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-Glucose Co-transporter 2 Inhibitors in Patients with Heart Failure with Preserved Ejection Fraction: Proposed Mechanisms, Recent Evidence, and Clinical Implications.
    Plosker A; Frishman WH
    Cardiol Rev; 2024 May-Jun 01; 32(3):263-266. PubMed ID: 36728757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on heart failure with preserved ejection fraction in diabetic patients: a meta-analysis.
    Albulushi A; Tanoh DB; Almustafa A; Al Matrooshi N; Zolty R; Lowes B
    Cardiovasc Diabetol; 2024 Aug; 23(1):324. PubMed ID: 39217337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction.
    Clemmer JS; Ward TJ; Lirette ST
    ESC Heart Fail; 2023 Jun; 10(3):2010-2018. PubMed ID: 37042079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chapter 3: Clinical Trials of Sodium-Glucose Co-Transporter-2 Inhibitors for Treatment of Heart Failure.
    Greene SJ; Butler J; Kosiborod MN
    Am J Med; 2024 Feb; 137(2S):S25-S34. PubMed ID: 38184323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB; Kaplinsky E; Zambrano MR; Chaume LT; Rosas JM
    Drugs Context; 2023; 12():. PubMed ID: 36660013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.